Oakbrook Investments LLC Boosts Position in Laboratory Corp. of America Holdings (LH)

Share on StockTwits

Oakbrook Investments LLC increased its holdings in shares of Laboratory Corp. of America Holdings (NYSE:LH) by 38.2% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,860 shares of the medical research company’s stock after purchasing an additional 3,000 shares during the quarter. Oakbrook Investments LLC’s holdings in Laboratory Corp. of America were worth $1,886,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of LH. GSA Capital Partners LLP increased its stake in Laboratory Corp. of America by 34.0% during the 1st quarter. GSA Capital Partners LLP now owns 3,441 shares of the medical research company’s stock worth $557,000 after purchasing an additional 874 shares in the last quarter. Commonwealth Equity Services LLC boosted its position in Laboratory Corp. of America by 17.3% during the 1st quarter. Commonwealth Equity Services LLC now owns 11,518 shares of the medical research company’s stock worth $1,863,000 after acquiring an additional 1,702 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Laboratory Corp. of America by 5.7% during the 1st quarter. The Manufacturers Life Insurance Company now owns 110,873 shares of the medical research company’s stock worth $17,933,000 after acquiring an additional 5,964 shares during the last quarter. Element Capital Management LLC acquired a new position in Laboratory Corp. of America during the 1st quarter worth approximately $215,000. Finally, LPL Financial LLC boosted its position in Laboratory Corp. of America by 30.1% during the 1st quarter. LPL Financial LLC now owns 5,311 shares of the medical research company’s stock worth $859,000 after acquiring an additional 1,230 shares during the last quarter. 92.18% of the stock is owned by institutional investors and hedge funds.

NYSE LH opened at $172.60 on Friday. The company has a market capitalization of $17.57 billion, a PE ratio of 16.16, a P/E/G ratio of 1.73 and a beta of 0.97. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.42 and a quick ratio of 1.32. Laboratory Corp. of America Holdings has a 12 month low of $147.70 and a 12 month high of $190.35.

Laboratory Corp. of America (NYSE:LH) last announced its quarterly earnings results on Wednesday, July 25th. The medical research company reported $2.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.92 by $0.06. The business had revenue of $2.87 billion during the quarter, compared to the consensus estimate of $2.85 billion. Laboratory Corp. of America had a return on equity of 16.38% and a net margin of 11.59%. The company’s quarterly revenue was up 13.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.47 EPS. On average, sell-side analysts forecast that Laboratory Corp. of America Holdings will post 11.52 earnings per share for the current year.

A number of equities analysts have weighed in on the company. Argus reaffirmed a “buy” rating on shares of Laboratory Corp. of America in a research report on Wednesday, August 22nd. Mizuho reaffirmed a “hold” rating and set a $189.00 price target on shares of Laboratory Corp. of America in a research report on Thursday, July 26th. ValuEngine downgraded Laboratory Corp. of America from a “buy” rating to a “hold” rating in a research report on Wednesday, July 4th. Bank of America assumed coverage on Laboratory Corp. of America in a research report on Friday. They set a “buy” rating for the company. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $220.00 price target on shares of Laboratory Corp. of America in a research report on Friday, July 20th. Six analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $197.44.

About Laboratory Corp. of America

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens.

Recommended Story: Moving Average (MA)

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Citizens Financial Group Inc  Holdings Increased by Paloma Partners Management Co
Citizens Financial Group Inc Holdings Increased by Paloma Partners Management Co
Brokerages Set $32.00 Target Price for Guaranty Bancshares, Inc.
Brokerages Set $32.00 Target Price for Guaranty Bancshares, Inc.
Paloma Partners Management Co Has $4.38 Million Position in Nutrien Ltd
Paloma Partners Management Co Has $4.38 Million Position in Nutrien Ltd
Paloma Partners Management Co Purchases New Position in Thomson Reuters Corp
Paloma Partners Management Co Purchases New Position in Thomson Reuters Corp
Seadrill Partners LLC  Shares Bought by Q Global Advisors LLC
Seadrill Partners LLC Shares Bought by Q Global Advisors LLC
Hilltop Holdings Inc. Has $3.27 Million Position in FibroGen Inc
Hilltop Holdings Inc. Has $3.27 Million Position in FibroGen Inc


© 2006-2018 Ticker Report